Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Jan 2024
New medical treatments will use genetic scissors, and other clever tricks
13 November 2023 - New medicines to treat sickle cell disease and beta thalassaemia, two genetic blood disorders, will make headlines ...
Posted by Michael Wonder on 01 Jan 2024
New Zealand Pharmaceutical Schedule - 1 January 2024
1 January 2024 - The January 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Jan 2024
How lowering the price of a common asthma drug made it harder to get
29 December 2023 - To avoid Medicaid penalties, Glaxo and other drug makers lowered prices. ...
Posted by Michael Wonder on 01 Jan 2024
PBS medicines to cost Aussies more from today; safety net thresholds also increase
1 January 2024 - Sick Australians who need PBS prescription medicines will be coughing up more from today. ...
Posted by Michael Wonder on 01 Jan 2024
Schedule of Pharmaceutical Benefits - 1 January 2024
1 January 2024 - The January 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 29 Dec 2023
Biden Administration’s Medicare drug price negotiations will face major tests in 2024
28 December 2023 - US patients and drug makers will get a first glimpse of how much Medicare can negotiate down ...
Posted by Michael Wonder on 29 Dec 2023
Father of two has to get cancer treatment in Germany after PHARMAC complications
21 December 2023 - An Auckland man has resorted to treatment for an aggressive bone marrow cancer in Germany after ...
Posted by Michael Wonder on 29 Dec 2023
Medytox submits BLA for non-animal-derived liquid BTX formulation in US
28 December 2023 - Medytox said it has submitted a biologics license application to the US FDA for MT10109L, a ...
Posted by Michael Wonder on 29 Dec 2023
Opdualag licensed for patients with advanced melanoma
27 December 2023 - The MHRA has today approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of ...
Posted by Michael Wonder on 28 Dec 2023
Swissmedic approves Beyfortus for RSV prophylaxis in newborns, infants and young children
28 December 2023 - Following a thorough review, Swissmedic has authorised the medicinal product Beyfortus from marketing authorisation holder Sanofi-Aventis (Suisse). ...
Posted by Michael Wonder on 28 Dec 2023
Application for COVID-19 vaccine Nuvaxovid against Omicron variant XBB.1.5 withdrawn
18 December 2023 - The manufacturer Novavax is no longer pursuing marketing authorisation for its COVID-19 vaccine in Switzerland. ...
Posted by Michael Wonder on 28 Dec 2023
Public Summary Documents – September 2023 PBAC meeting
22 December 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the September 2023 PBAC ...
Posted by Michael Wonder on 28 Dec 2023
Resubmission of arimoclomol new drug application to the US FDA
27 December 2023 - Zevra Therapeutics today announced it resubmitted its new drug application for arimoclomol, an investigational therapeutic candidate for ...
Posted by Michael Wonder on 28 Dec 2023
Milestone Pharmaceuticals receives refusal to file letter from US FDA for new drug application for etripamil in the treatment of PSVT
26 December 2023 - Milestone Pharmaceuticals announced today that the Company received a refusal to file letter from the US ...
Posted by Michael Wonder on 28 Dec 2023
Celltrion seeks approval for Xolair biosimilar in Canada
27 December 2023 - Celltrion said Wednesday that it has completed the submission of its marketing authorisation application for its ...